Serum levels of NT-proBNP as surrogate for cardiac amyloid burden: New evidence from gadolinium-enhanced cardiac magnetic resonance imaging in patients with amyloidosis

Amyloid

Volumn 16, Issue 4, 2009, Pages 187-195

  Lehrke, Stephanie ^a   Steen, Henning ^a   Kristen, Arnt V ^a   Merten, Constanze ^a   Lossnitzer, Dirk ^a   Dengler, Thomas J ^b   Katus, Hugo A ^a   Giannitsis, Evangelos ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b Klinikum am Plattenwald   (Germany)

Author keywords

Cardiac amyloidosis; Cardiac magnetic resonance imaging; Natriuretic peptides; Prognosis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; EVENT FREE SURVIVAL; FEMALE; HEART AMYLOIDOSIS; HEART EJECTION FRACTION; HEART FAILURE; HEART STROKE VOLUME; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

AMYLOID; AMYLOIDOSIS; CARDIOMYOPATHIES; CONTRAST MEDIA; FEMALE; GADOLINIUM; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS;

EID: 73349127130     PISSN: 13506129     EISSN: 17442818     Source Type: Journal    
DOI: 10.3109/13506120903421538     Document Type: Article

References (29)

1. Dubrey SW, Cha K, Anderson J, Chamarthi B, Reisinger J, Skinner M, Falk RH. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM 1998;91:141-157.
2. Kyle RA, Greipp PR, O'Fallon WM. Primary systemic amyloidosis: multivariate analysis for prognostic factors in 168 cases. Blood 1986;68:220-224.
3. Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL, Anderson JJ, O'Hara C, Finn KT, Libbey CA, Wiesman J, Quillen K, Swan N, Wright DG. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004;140:85-93.
4. Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation 2005;112:2047-2060.
5. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, McConnell JP, Litzow MR, Gastineau DA, Tefferi A, Inwards DJ, Micallef IN, Ansell SM, Porrata LF, Elliott MA, Hogan WJ, Rajkumar SV, Fonseca R, Greipp PR, Witzig TE, Lust JA, Zeldenrust SR, Snow DS, Hayman SR, McGregor CG, Jaffe AS. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2004;104: 1881-1887.
6. Palladini G, Campana C, Klersy C, Balduini A, Vadacca G, Perfetti V, Perlini S, Obici L, Ascari E, d'Eril GM, Moratti R, Merlini G. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003;107:2440-2445.
7. Suhr OB, Anan I, Backman C, Karlsson A, Lindqvist P, Mörner S, Waldenström A. Do troponin and B-natriuretic peptide detect cardiomyopathy in transthyretin amyloidosis? J Intern Med 2008;263:294-301.
8. Kristen AV, Perz JB, Schonland SO, Hegenbart U, Schnabel PA, Kristen JH, Goldschmidt H, Katus HA, Dengler TJ. Non-invasive predictors of survival in cardiac amyloidosis. Eur J Heart Fail 2007;9:617-624.
9. Takemura G, Takatsu Y, Doyama K, Itoh H, Saito Y, Koshiji M, Ando F, Fujiwara T, Nakao K, Fujiwara H. Expression of atrial and brain natriuretic peptides and their genes in hearts of patients with cardiac amyloidosis. J Am Coll Cardiol 1998;31:754-765.
10. Keenan NG, Pennell DJ. CMR of ventricular function. Echocardiography 2007;24:185-193.
11. Krombach GA, Hahn C, Tomars M, Buecker A, Grawe A, Günther RW, Kühl HP. Cardiac amyloidosis: MR imaging findings and T1 quantification, comparison with control subjects. J Magn Reson Imaging 2007;25:1283-1287.
12. van den Driesen RI, Slaughter RE, Strugnell WE. MR findings in cardiac amyloidosis. AJR 2006;186:1682-1685.
13. Vogelsberg H, Mahrholdt H, Deluigi CC, Yilmaz A, Kispert EM, Greulich S, Klingel K, Kandolf R, Sechtem U. Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol 2008;51:1031-1032.
14. Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I, Sheppard MN, Poole-Wilson PA, Hawkins PN, Pennell DJ. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2005;111:186-193.
15. Perugini E, Rapezzi C, Piva T, Leone O, Bacchi-Reggiani L, Riva L, Salvi F, Lovato L, Branzi A, Fattori R. Non-invasive evaluation of the myocardial substrate of cardiac amyloidosis by gadolinium cardiac magnetic resonance. Heart 2006;92: 343-349.
16. Hosch W, Kristen AV, Libicher M, Dengler TJ, Aulmann S, Heye T, Schnabel PA, Schirmacher P, Katus HA, Kauczor HU, Longerich T. Late enhancement in cardiac amyloidosis: correlation of MRI enhancement pattern with histopathological findings. Amyloid 2008;15:196-204.
17. Maceira AM, Prasad SK, Hawkins PN, Roughton M, Pennell DJ. Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. J Cardiovasc Magn Reson 2008;10:54.
18. Ruberg FL, Appelbaum E, Davidoff R, Ozonoff A, Kissinger KV, Harrigan C, Skinner M, Manning WJ. Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in light-chain cardiac amyloidosis. Am J Cardiol 2009;103:544-549.
19. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, Merlini G, Moreau P, Ronco P, Sanchorawala V, Sezer O, Solomon AG. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005;79:319-328.
20. Khouri SJ, Maly GT, Suh DD, Walsh TE. A practical approach to the echocardiographic evaluation of diastolic function. J Am Soc Echocardiogr 2004;17:290-297.
21. Palladini G, Lavatelli F, Russo P, Perlini S, Perfetti V, Bosoni T, Obici L, Bradwell AR, D'Eril GM, Fogari R, Moratti R, Merlini G. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 2006;107:3854-3858.
22. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, Greipp PR, Witzig TE, Lust JA, Rajkumar SV, Fonseca R, Zeldenrust SR, McGregor CG, Jaffe AS. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004;22:3751-3757.
23. Liang F, Gardner DG. Mechanical strain activates BNP gene transcription through a p38/NF-kappaB-dependent mechanism. J Clin Invest 1999;104:1603-1612.
24. Takemura G, Fujiwara H, Yoshida H Mukoyama M, Saito Y, Nakao K, Fujiwara T, Uegaito T, Imura H, Kawai C. Identification and distribution of atrial natriuretic polypeptide in ventricular myocardium of humans with myocardial infarction. J Pathol 1990;161:285-292.
25. Hasegawa K, Fujiwara H, Doyama K, Mukoyama M, Nakao K, Fujiwara T, Imura H, Kawai C. Ventricular expression of brain natriuretic peptide in hypertrophic cardiomyopathy. Circulation 1993;88:372-380.
26. Nordlinger M, Magnani B, Skinner M, Falk RH. Is elevated plasma B-natriuretic peptide in amyloidosis simply a function of the presence of heart failure? Am J Cardiol 2005;96:982-984.
27. Liao R, Jain M, Teller P, Connors LH, Ngoy S, Skinner M, Falk RH, Apstein CS. Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation 2001;104:1594-1597.
28. Richards AM, Nicholls MG, Yandle TG Frampton C, Espiner EA, Turner JG, Buttimore RC, Lainchbury JG, Elliott JM, Ikram H, Crozier IG, Smyth DW. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998;97: 1921-1929.
29. Anwaruddin S, Lloyd-Jones DM, Baggish, A Chen A, Krauser D, Tung R, Chae C, Januzzi JL Jr. Renal function, congestive heart failure, and amino-terminal probrain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol 2006;47: 91-97.